NDA 221337 · Industrial Welding Supply CO Of Harvey INC
Medical Air, Usp
· Inhalation
Last checked: Nov 20, 2026Latest source record: Feb 17, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
Feb 17, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
3
0 Phase 3, 2 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 17, 2026 Original approval Letter
1 products under this application
- MEDICAL AIR, USP · · GAS, INHALATION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Medical Air, Usp" as an intervention, any sponsor and status, largest first.
- Facilitation of Extinction Retention and Reconsolidation Blockade by IV Allopregnanolone in PTSD.Recruiting
Massachusetts General HospitalAcademic, hospital or other
NCT07079761 · 96 participants (planned) · Start Aug 4, 2025 · Primary completion Apr 30, 2027
Drug: Allopregnanolone (Allo) with 6% USP Dexolve (sulfobutyl ether-beta-cyclodextrin sodium salt) in 0.9% saline for IV infusion will be provided by the University of California, Davis, GMP manufacturer.; Allopregnanolone (Allo) with 6% USP Dexolve (sulfobutyl ether-beta-cyclodextrin sodium salt) in 0.9% saline for IV infusion will be provided by the University of California, Davis, GMP manufacturer. · For: Post Traumatic Stress Disorder
Sites: Boston, Massachusetts
- Long-Term Outcomes Following HBOTRecruiting
Summit Hyperbarics and WellnessAcademic, hospital or other
NCT07732374 · 35 participants (planned) · Start Jun 18, 2026 · Primary completion Jun 18, 2027
Drug: Hyperbaric Oxygen Therapy (HBOT) · For: Traumatic Brain Injury; Post-Concussive Symptoms; Post-Traumatic Stress Disorder
Sites: Boise, Idaho
- Assessing Effects of Heparin Priming and Pass Number on Tissue Quality of Fine Needle BiopsiesTerminated
University of MichiganAcademic, hospital or other
NCT04764396 · 2 participants · Start Mar 12, 2021 · Primary completion Apr 6, 2021
Drug: Saline · For: Pancreas; Mass Lesion
Sites: Ann Arbor, Michigan
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.